Latest & greatest articles for magnesium

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on magnesium or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on magnesium and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for magnesium

161. Review: antenatal magnesium sulphate prevents cerebral palsy in preterm infants

Review: antenatal magnesium sulphate prevents cerebral palsy in preterm infants Review: antenatal magnesium sulphate prevents cerebral palsy in preterm infants | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional (...) accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: antenatal magnesium sulphate prevents cerebral palsy in preterm infants Article Text Therapeutics Review: antenatal magnesium sulphate prevents cerebral palsy in preterm infants Statistics from Altmetric.com Question

2009 Evidence-Based Medicine

162. Magnesium sulphate effective neuroprotection for the foetus of women at risk of preterm delivery

Magnesium sulphate effective neuroprotection for the foetus of women at risk of preterm delivery PEARLS Practical Evidence About Real Life Situations PEARLS are succinct summaries of Cochrane Systematic Reviews for primary care practitioners. They Magnesium sulphate effective neuroprotection for the foetus of women at risk of preterm delivery Clinical question How effective is magnesium sulphate as a neuroprotective agent when given to women considered at risk of preterm delivery? Bottom line (...) Antenatal magnesium sulphate therapy given to women at risk of preterm delivery, substantially reduced the risk of cerebral palsy in their child (NNT* 63). There was also a significant reduction in the rate of substantial gross motor dysfunction. The loading dose given was 4g or 6g IV, with a maintenance dose varying from nil (2 studies) to 1g/hour (1 study) and 2-3 g/hour (2 studies). The magnesium sulphate was given 24 hours prior to delivery in 3 studies, with no specific time interval reported in 2

2009 Cochrane PEARLS

163. Intraarticular injection of magnesium sulphate and/or bupivacaine for postoperative analgesia after arthroscopic knee surgery Full Text available with Trip Pro

Intraarticular injection of magnesium sulphate and/or bupivacaine for postoperative analgesia after arthroscopic knee surgery Intraarticular bupivacaine is often used for prevention of pain after arthroscopic knee surgery. Intraarticular magnesium, a N-methyl-D-aspartate receptor blocker, would be of particular interest in either producing postoperative analgesia or enhancing the analgesic effect of intraarticular bupivacaine. We designed this study to determine whether intraarticular magnesium (...) sulfate or bupivacaine results in a decrease in visual analog scale (VAS) score followed by a decrease in analgesic requirement and whether their combination would provide more reduction in VAS, and subsequently less analgesic requirement, than either drug alone.One-hundred and eight patients undergoing arthroscopic meniscectomy were randomized blindly into one of four parallel groups. The saline placebo group (group S) received 20 mL of isotonic saline, and the magnesium group (group M) received 20

2008 EvidenceUpdates Controlled trial quality: uncertain

164. Nexium (esomeprazole magnesium) For Delayed-Release Oral Suspension

Nexium (esomeprazole magnesium) For Delayed-Release Oral Suspension Drug Approval Package: Nexium (esomeprazole magnesium) NDA #022101 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Nexium (esomeprazole magnesium) For Delayed-Release Oral Suspension Company: AstraZeneca LP Application No.: 022101 Approval Date: 2/27/2008 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF

2008 FDA - Drug Approval Package

165. Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation

Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation Shepherd J (...) , Jones J, Frampton G K, Tanajewski L, Turner D, Price A CRD summary RCTs directly comparing intravenous magnesium sulphate with sotalol were not identified, but the authors did conclude that intravenous magnesium is effective in preventing atrial fibrillation in patients undergoing coronary artery bypass graft when compared to controls. This was a well conducted piece of research, which considered limitations with the included studies. The authors' conclusions are likely to be reliable. Authors

2008 DARE.

166. Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation

Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation Shepherd J (...) , Jones J, Frampton GK, Tanajewski L, Turner D, Price A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Shepherd J, Jones J, Frampton GK, Tanajewski L, Turner D, Price A. Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation. Southampton

2008 Health Technology Assessment (HTA) Database.

167. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. Full Text available with Trip Pro

A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. Research suggests that fetal exposure to magnesium sulfate before preterm birth might reduce the risk of cerebral palsy.In this multicenter, placebo-controlled, double-blind trial, we randomly assigned women at imminent risk for delivery between 24 and 31 weeks of gestation to receive magnesium sulfate, administered intravenously as a 6-g bolus followed by a constant infusion of 2 g per hour, or matching (...) placebo. The primary outcome was the composite of stillbirth or infant death by 1 year of corrected age or moderate or severe cerebral palsy at or beyond 2 years of corrected age.A total of 2241 women underwent randomization. The baseline characteristics were similar in the two groups. Follow-up was achieved for 95.6% of the children. The rate of the primary outcome was not significantly different in the magnesium sulfate group and the placebo group (11.3% and 11.7%, respectively; relative risk, 0.97

2008 NEJM Controlled trial quality: predicted high

168. Magnesium sulfate for persistent pulmonary hypertension of the newborn. (Abstract)

Magnesium sulfate for persistent pulmonary hypertension of the newborn. Persistent pulmonary hypertension of the newborn (PPHN) occurs in approximately 1.9 per 1000 newborns and may be more frequent in developing countries. There is strong evidence for the use of inhaled nitric oxide (iNO) and extra corporeal membrane oxygenation (ECMO) in the treatment of PPHN. However, many developing countries do not have access or the technical expertise required for these expensive therapies. Magnesium (...) sulfate is a potent vasodilator and hence has the potential to reduce the high pulmonary arterial pressures associated with PPHN. If magnesium sulfate were found to be effective in the treatment of PPHN, this could be a cost effective and potentially life-saving therapy.To evaluate the use of magnesium sulfate compared with placebo or standard ventilator management alone, sildenafil infusion, adenosine infusion, or inhaled nitric oxide on mortality or the use of backup iNO or ECMO in term and near

2007 Cochrane

169. Intravenous and nebulised magnesium sulphate for acute asthma: systematic review and meta-analysis

Intravenous and nebulised magnesium sulphate for acute asthma: systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 DARE.

170. Use of intravenous magnesium to treat acute onset atrial fibrillation: a meta-analysis Full Text available with Trip Pro

Use of intravenous magnesium to treat acute onset atrial fibrillation: a meta-analysis Use of intravenous magnesium to treat acute onset atrial fibrillation: a meta-analysis Use of intravenous magnesium to treat acute onset atrial fibrillation: a meta-analysis Ho K M, Sheridan D J, Paterson T CRD summary This well-conducted review found that intravenous magnesium is not effective in converting acute onset atrial fibrillation to sinus rhythm in patients with a normal serum magnesium (...) concentration. The addition of intravenous magnesium to digoxin reduces fast ventricular response rates, but is less effective than other calcium antagonists or amiodarone. These findings are likely to be reliable. Authors' objectives To determine the effectiveness of intravenous magnesium in the conversion of acute onset atrial fibrillation (AF) to sinus rhythm, and in reducing ventricular response and risk of bradycardia. Searching The Cochrane CENTRAL Register, EMBASE and MEDLINE were searched to May

2007 DARE.

171. ED use of magnesium sulphate improved rate control in atrial fibrillation with rapid ventricular response Full Text available with Trip Pro

ED use of magnesium sulphate improved rate control in atrial fibrillation with rapid ventricular response ED use of magnesium sulphate improved rate control in atrial fibrillation with rapid ventricular response | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here ED use of magnesium sulphate improved rate control in atrial fibrillation with rapid ventricular response Article Text Therapeutics ED use of magnesium sulphate improved rate

2006 Evidence-Based Medicine

172. Pantoprazole magnesium

Pantoprazole magnesium Common Drug Review CEDAC Meeting – June 21, 2006 Page 1 of 2 Notice of CEDAC Final Recommendation – July 20, 2006 CEDAC FINAL RECOMMENDATION and REASONS for RECOMMENDATION PANTOPRAZOLE MAGNESIUM (Pantoloc M™ – Altana Pharma Inc.) Description: Pantoprazole magnesium is a new salt form of pantoprazole, a widely used proton pump inhibitor (PPI). It is approved for use in conditions where a reduction of gastric acid is required, such as the following: duodenal ulcer, gastric (...) ulcer, reflux esophagitis and symptomatic gastro- esophageal reflux disease (such as, acid regurgitation and heartburn). Additionally, pantoprazole, in combination with clarithromycin and either amoxicillin or metronidazole, is approved for use in the treatment of patients with an active duodenal ulcer who are H. pylori positive. Dosage Forms: 40 mg enteric coated tablet Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that pantoprazole magnesium be listed in a similar

2006 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

173. Combined calcium, magnesium and potassium supplementation for the management of primary hypertension in adults. (Abstract)

Combined calcium, magnesium and potassium supplementation for the management of primary hypertension in adults. Previous research suggests that increasing dietary intakes of calcium, potassium or magnesium separately may reduce BP to a small degree over the short term. It is unclear whether increasing intakes of a combination of these minerals produces a larger reduction in BP.To evaluate the effects of combined mineral supplementation as a treatment for primary hypertension in adults.We (...) searched the Cochrane Library, MEDLINE, EMBASE, Science Citation Index, ISI Proceedings, ClinicalTrials.gov, Current Controlled Trials, CAB abstracts, and reference lists of systematic reviews, meta-analyses and randomised controlled trials (RCTs) included in the review. The search was unrestricted by language or publication status.Inclusion criteria were: 1) RCTs of a parallel or crossover design comparing oral supplements comprising a combination of potassium, and/or calcium, and/or magnesium

2006 Cochrane

174. Review: magnesium prophylaxis after cardiac surgery reduces the risk of arrhythmia and atrial fibrillation Full Text available with Trip Pro

Review: magnesium prophylaxis after cardiac surgery reduces the risk of arrhythmia and atrial fibrillation Review: magnesium prophylaxis after cardiac surgery reduces the risk of arrhythmia and atrial fibrillation | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: magnesium prophylaxis after cardiac surgery reduces the risk of arrhythmia and atrial fibrillation Article Text Treatment Review: magnesium prophylaxis after cardiac

2006 Evidence-Based Nursing

175. Intravenous magnesium in shock resistant tachyarrhythmias

Intravenous magnesium in shock resistant tachyarrhythmias BestBets: Intravenous Magnesium in shock-resistant tachyarrhythmias Intravenous Magnesium in shock-resistant tachyarrhythmias Report By: Ayan Sen - Senior House Officer, Anaesthetics and Intensive Care Search checked by Shweta Gidwani - Clinical Effectiveness Fellow Institution: Fairfield Hospital,Bury Date Submitted: 21st December 2005 Date Completed: 1st March 2006 Last Modified: 21st December 2005 Status: Green (complete) Three Part (...) Question Does [intravenous magnesium] lead to [return of spontaneous circulation] in [shock-resistant tachyarrhythmias] Clinical Scenario A 65 year old man suffered a witnessed out-of-hospital cardiac arrest. He received 20 minutes of basic and advances cardiac life support measures in the field. On arrival in the emergency department, the rhythm showed persistent ventricular fibrillation and he continued to be pulseless. You decide to continue another cycle of defibrillation and think of anti

2006 BestBETS

176. Cost-effectiveness of prophylactic magnesium sulphate for 9996 women with pre-eclampsia from 33 countries: economic evaluation of the Magpie Trial

Cost-effectiveness of prophylactic magnesium sulphate for 9996 women with pre-eclampsia from 33 countries: economic evaluation of the Magpie Trial Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 NHS Economic Evaluation Database.

177. Effects of oral magnesium supplementation on glycaemic control in type 2 diabetes: a meta-analysis of randomized double-blind controlled trials

Effects of oral magnesium supplementation on glycaemic control in type 2 diabetes: a meta-analysis of randomized double-blind controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 DARE.

178. Nebulized magnesium sulfate in the management of acute exacerbations of asthma

Nebulized magnesium sulfate in the management of acute exacerbations of asthma Nebulized magnesium sulfate in the management of acute exacerbations of asthma Nebulized magnesium sulfate in the management of acute exacerbations of asthma Villeneuve E J, Zed P J CRD summary This review concluded that there was insufficient evidence to determine the role of nebulised magnesium sulphate in the treatment of acute exacerbations of asthma. The review had methodological limitations (limited search (...) and no validity assessment) and only six small studies were included. However, the authors' cautious conclusions, and their recommendation for further research, appear appropriate. Authors' objectives To evaluate the efficacy and safety of nebulised magnesium sulphate (NMS) for treating acute exacerbations of asthma. Searching MEDLINE/PubMed and EMBASE were searched to October 2005; the search terms were reported. The searches were restricted to publications in the English language. Abstracts were excluded

2006 DARE.

179. Magnesium sulphate for treatment of severe tetanus: a randomised controlled trial. (Abstract)

Magnesium sulphate for treatment of severe tetanus: a randomised controlled trial. The most common cause of death in individuals with severe tetanus in the absence of mechanical ventilation is spasm-related respiratory failure, whereas in ventilated patients it is tetanus-associated autonomic dysfunction. Our aim was to determine whether continuous magnesium sulphate infusion reduces the need for mechanical ventilation and improves control of muscle spasms and autonomic instability.We did (...) a randomised, double blind, placebo controlled trial in 256 Vietnamese patients over age 15 years with severe tetanus admitted to the Hospital for Tropical Medicine, Ho Chi Minh City, Vietnam. Participants were randomly assigned magnesium sulphate (n=97) or placebo solution (n=98) intravenously for 7 days. The primary outcomes were requirement of assisted ventilation and of drugs to control muscle spasms and cardiovascular instability within the 7-day study period. Analyses were done by intention to treat

2006 Lancet Controlled trial quality: predicted high

180. The Magic of Magnesium as an Adjunct in Atrial Fibrillation

The Magic of Magnesium as an Adjunct in Atrial Fibrillation The Magic of Magnesium as an Adjunct in Atrial Fibrillation « Sinai EM Journal Club Emergency Medicine Discussion Forum The Magic of Magnesium as an Adjunct in Atrial Fibrillation Dinali did a stellar job this month at Journal Club; not only was her talk thought-provoking and clinically relevant, but I learned more about the history of of than I would have ever thought possible. This month’s JC was primarily about Davey and Teubner’s (...) AEM paper on using Magnesium sulfate as an adjunct to “usual care” for rate control in atrial fibrillation ( ). We also touched upon some data from an all-Greek study in the Int’l Journal of Cardiology on Mg alone vs diltiazem alone in A-fib ( ). Davey and Taubner looked at 199 Australians with rapid afib in this prospective, randomized, double-blinded, placebo-controlled trial. They got “standard rate-reduction agents” plus placebo, or te same agents plus 20 mEq of magnesium sulfate infused over

2006 Sinai EM Journal Club